RSLS News and Press, ReShape Lifesciences Inc. From 05/29/24

A look at the top 10 most actives in the United States ReShape Lifesciences Inc. (RSLS) rose 89.7% to $0.3942 on volume of 109,324,190 shares Faraday Future Intelligent Electric Inc. (FFIE) fell 30.3% to $0.8151 on volume of 100,649,842 shares Innovative Eyewear Inc. (LUCY) rose 61.0% to ...

2024-05-29 10:00:15 ET More on Health Care Select Sector SPDR XLV: Healthcare Is Ripe For Buying, Despite Patent Cliff XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care Short interest in S&P 500 ...

2024-05-17 20:57:06 ET ReShape Lifesciences, Inc. (RSLS) Q1 2024 Earnings Conference Call May 15, 2024, 16:30 ET Company Participants Michael Miller - Investor Relatons Paul Hickey - President, CEO & Director Thomas Stankovich - CFO Conference Call Part...

Commercial Launch of Next-Generation Lap-Band® 2.0 FLEX Continues Significant Reduction in Overall Operating Expenses of 51% in the First Quarter of 2024 Compared to the First Quarter of 2023 Implementation of 2024 Cost Reduction Plan Continues, Expected to Reduce Operating...

Bank of Georgia Group Plc (BDGSF) is expected to report for Q1 2024 iCad Inc. (ICAD) is expected to report for Q1 2024 Yasheng Group (HERB) is expected to report for Q1 2024 Bit Digital Inc. (BTBT) is expected to report $0.01 for Q1 2024 Estrella Immunopharma Inc. (ESLA) is expect...

IRVINE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the first quarter ended March 31, 2024, including a co...

2024-05-09 12:22:56 ET More on ReShape Lifesciences ReShape Lifesciences gets notice of allowance for additional U.S. patent ReShape Lifesciences sees 55.4% fall in Y/Y expenses in 2024 with cost cut plan Read the full article on Seeking Alpha For further det...

Completed First Surgeries With Next-Generation Lap-Band ® 2.0 FLEX 2024 Operating Expenses Expected to Decrease by more than 50% Compared to 2023; Reaffirming Commitment to Profitability Conference Call to be Held at 4:30 pm ET Today IRVINE, Calif., April 01, 2024...

2024-03-28 08:56:46 ET More on ReShape Lifesciences ReShape Lifesciences sees 55.4% fall in Y/Y expenses in 2024 with cost cut plan Seeking Alpha’s Quant Rating on ReShape Lifesciences Historical earnings data for ReShape Lifesciences Financial informa...

IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that the company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for...